Roland Solensky, MD
Allergy & Immunology · Corvallis, ORNPI 1033169271
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (40.5%), food and beverage and education — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by GSK at 40.5% of the total. Reporting peaked in 2022 at $192 and has fallen 82.1% since, to $34 in 2025. That places this record below the midpoint for allergy & immunology clinicians in OR, where the typical reported total is $1,736.
Across 13 payments — averaging $34.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$180
- Regeneron Healthcare Solutions, Inc.$98
- Bio Products Laboratory USA, Inc.$63
- Biocryst US Sales Co., LLC$29
- Dermavant Sciences, Inc.$26
- CSL Behring$18
- plus $31 from 3 others
Across 15 payments — averaging $3454.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$27K
- Alk-abello, Inc$25K
What the payments were for
- Consulting fees$18040%
- Food & beverage$14833%
- Education$11626%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 2 | $180 |
| Regeneron Healthcare Solutions, Inc. | 1 | $98 |
| Bio Products Laboratory USA, Inc. | 4 | $63 |
| Biocryst US Sales Co., LLC | 1 | $29 |
| Dermavant Sciences, Inc. | 1 | $26 |
| CSL Behring | 1 | $18 |
| Sanofi | 1 | $13 |
| Grifols USA, LLC | 1 | $12 |
| Organon | 1 | $6 |
How this compares
$445 in reported general payments places this provider in the 30th percentile of 33 allergy & immunology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 31 | $125,041 |
| NucalaMepolizumab | 19 | $65,373 |
| Spiriva RespimatTiotropium Bromide | 51 | $37,574 |
| Zileuton ErZileuton | 12 | $34,798 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 37 | $33,026 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $25,358 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 156 | $21,162 |
| SymbicortBudesonide/Formoterol Fumarate | 76 | $18,499 |
| Advair HfaFluticasone Propion/Salmeterol | 37 | $17,016 |
| Serevent DiskusSalmeterol Xinafoate | 32 | $15,423 |
| Breo ElliptaFluticasone/Vilanterol | 36 | $14,471 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 58 | $12,324 |
| Qvar RedihalerBeclomethasone Dipropionate | 38 | $12,178 |
| Ipratropium Bromide | 123 | $8,624 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $7,812 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $180 | $116,786112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 33 allergy & immunology providers in Oregon.
Other allergy & immunology in Corvallis
- Adam WilliamsBend$138K
- Shyam JoshiPortland$116K
- Stephen FritzHappy Valley$42K
- Anthony MontanaroPortland$25K
- Karen AnsteyPortland$20K
- Michael OsbornePortland$11K
- Jessica MacdougallPortland$11K
- Kraig JacobsonEugene$7K
- James SweetTualatin$7K
- Benjamin RahoySalem$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.